Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
Reuters on MSN2d
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesAmericans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Clinical trial data from Eli Lilly and Novo Nordisk suggest fewer than 10 ... 37% of people using a GLP-1 drug for either ...
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Two weeks ago, the Health Secretary announced the UK government would be spending £300m on weight loss drug trials with ...
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback